Category

News
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). This study evaluated addition of daratumumab (D) to RVd in ASCTeligible NDMM patients. Patients (N=207) were randomized...
Continue Reading
Real world experience with early bortezomib therapy in multiple myeloma in Australia suggests that it is used in patients who are older and more vulnerable than those in clinical trials. A retrospective review has reported data from 74 patients at three Queensland hospitals who had newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation who were...
Continue Reading
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. Multiple myeloma (MM) is the third most common hematologic malignancy worldwide, characterized by excessive proliferation of monoclonal plasma cells. The development of novel anti-MM agents has expanded treatment options for MM patients and improved out-comes. Despite recent treatment advances, MM remains incurable, with...
Continue Reading
The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or relapsed/refractory multiple myeloma (MM). Daratumumab was previously approved as an intravenous treatment for patients with MM. The combination of daratumumab and hyaluronidase-fihj is co-formulated with recombinant human hyaluronidase PH20 to allow subcutaneous injection. The treatment is approved...
Continue Reading
A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might more effectively treat people with multiple myeloma, a study suggests. Its researchers also report that lowering levels of a particular protein on myeloma cells, MCL-1, may make them more responsive to treatments for this cancer....
Continue Reading
CURE® recently invited patients, survivors, caregivers, advocates and health care professionals to attend its first-ever live webinar, “Hear from the Experts: COVID-19 & Cancer Care for Patients.” Sponsored by Janssen and Pharmacyclics, the webinar was designed to provide those affected by chronic lymphocytic leukemia (CLL) and myeloma with information and updates as it pertained to...
Continue Reading
Patients with haematological cancers are at higher risk of COVID-19 infection and experience more severe disease compared to people with other cancers, say experts discussing the latest evidence on COVID-19. Speaking as part of an expert panel assembled for a COVID-19 webinar sponsored by Janssen-Cilag, Dr Benjamin Teh, an infectious diseases physician at the Peter...
Continue Reading
Madrid-based PharmaMar has submitted the protocol for a Phase 2 trial to the Spanish Medicines and Healthcare Products Agency (AEMPS) to test its multiple myeloma therapy Aplidin (plitidepsin) in people with COVID-19 pneumonia. The trial, named APLICOV, aims to recruit 160 patients across multiple sites in Spain and assess if Aplidin reduces the proportion of...
Continue Reading
A new study published in Leukemia revealed that researchers at the Institute of Cancer Research in London have found a new genetic test that could help doctors determine which patients with multiple myeloma are at “ultra high risk” of their cancer progressing aggressively in its early stages.1 The results of the research showed that a particular genetic...
Continue Reading
The immunosuppressant tocilizumab may be a promising option for myeloma patients with COVID-19, a case study from China suggests. Dr Changcheng Zheng, MD, of the University of Science and Technology of China and colleagues detailed the case of a 60-year-old man with multiple myeloma who was hospitalised with chest tightness and shortness of breath and subsequently...
Continue Reading
1 13 14 15 16 17 37

Floor 7, 90 The Terrace
Wellington Central
New Zealand